AbbVie reported third-quarter results that exceeded analyst estimates, posting a Non-GAAP EPS of $3.82 and revenue of $17.4 billion. Following these strong results, the company raised its financial guidance for the full year. Despite surpassing earnings expectations, AbbVie's stock experienced a dip.
The company raised its adjusted 2026 earnings forecast to $13.95–$13.99 per share, with strong growth in immunology and neuroscience and continued declines in Humira.
Read the full storyThe company reported quarterly revenue of $17.404 billion, exceeding analyst estimates, as growth in immunology and neuroscience drugs supported results despite lower Humira sales.